Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Jonathan K. Kish"'
1
Akademický článek
Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
Autor: Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Publikováno v: Cancer Medicine, Vol 7, Iss 9, Pp 4371-4378 (2018)
Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative bre
Externí odkaz: https://doaj.org/article/b658d3e9e1944667a90dfd4adc7700a6
Zobrazit plný text záznamu
4
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Autor: Aaron T. Gerds, Jingbo Yu, Robyn M. Scherber, Dilan Paranagama, Jonathan K. Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Naveen Pemmaraju
Publikováno v: Acta haematologica. 145(4)
Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume in patients with myelofibrosis, with a median time to response of 3 months. However, nearly 20% o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f584c91e1f3bb87993d6d324f1a12997
https://pubmed.ncbi.nlm.nih.gov/35008087
Zobrazit plný text záznamu
5
Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS)
Autor: Sudipto Mukherjee, Kristin M. Zimmerman Savill, Ajeet Gajra, Jonathan K. Kish, Cherrishe Brown-Bickerstaff, Danielle Gentile, Angelica Falkenstein, Talia Miller, Jalyna R. Laney, Ali McBride
Publikováno v: Journal of Clinical Oncology. 40:e19065-e19065
e19065 Background: ESAs are used in first-line treatment for symptomatic or transfusion-dependent anemia in patients (pts) with LR-MDS. Ultimately, the majority of pts with LR-MDS who receive an ESA will experience ESA treatment failure. This real-wo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3815cf92529e1df52fee6fbbdda04f9e
https://doi.org/10.1200/jco.2022.40.16_suppl.e19065
Zobrazit plný text záznamu
6
Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan
Autor: Jonathan K. Kish, Sandhya Mehta, Jackie Kwong, Clara Lam, Angelica Falkenstein, Cherrishe Brown-Bickerstaff, Dong Xiao, Bruce A. Feinberg
Publikováno v: Journal of Clinical Oncology. 40:1036-1036
1036 Background: Trastuzumab Deruxtecan (T-DXd) was associated with an increased risk of interstitial lung disease (ILD)/pneumonitis (P) in metastatic breast cancer (mBC) patients (pts) in clinical trials, leading to ILD/P monitoring and management g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e58713fa5b199930d7c8e4a9dac5dc3
https://doi.org/10.1200/jco.2022.40.16_suppl.1036
Zobrazit plný text záznamu
7
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting
Autor: Daniel M. Geynisman, Jonathan K. Kish, Angelica Falkenstein, Stephen Huo, Viviana Del Tejo, Lisa Rosenblatt, Sarah Guttenplan, Alexandrina Balanean, Bruce A. Feinberg
Publikováno v: Journal of Clinical Oncology. 40:4548-4548
4548 Background: In 1L therapy for aRCC, nivolumab plus ipilimumab (NIVO+IPI) and pembrolizumab plus axitinib (PEM+AXI) have demonstrated significantly improved clinical outcomes versus sunitinib in phase III trials. African American/Black (AA) patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d64f07551d0911422355c19b404bbbd7
https://doi.org/10.1200/jco.2022.40.16_suppl.4548
Zobrazit plný text záznamu
9
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA
Autor: Jonathan K. Kish, Agnieszka Cseh, Barbara Moehring, Wenbo Tang, Elizabeth Terlizzi, Edward S. Kim, Janakiraman Subramanian
Publikováno v: Clinical Lung Cancer. 22:292-300.e1
Background The ErbB family blocker, afatinib, is approved for patients with squamous cell carcinoma (SqCC) of the lung following platinum-doublet chemotherapy but has not been explored following immunochemotherapy. Here, we assessed the characteristi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a602af66e93620c21955c896ded0ecb0
https://doi.org/10.1016/j.cllc.2021.02.006
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje